Teva Pharmaceutical Valuation
| TEVJF Stock | USD 17.80 0.45 2.47% |
At this time, the company appears to be overvalued. Teva Pharmaceutical has a current Real Value of $14.59 per share. The regular price of the company is $17.8. Our model measures the value of Teva Pharmaceutical from inspecting the company fundamentals such as Operating Margin of 0.18 %, shares outstanding of 1.11 B, and Return On Equity of -0.24 as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Teva Pharmaceutical's price fluctuation is somewhat reliable at this time. Calculation of the real value of Teva Pharmaceutical is based on 3 months time horizon. Increasing Teva Pharmaceutical's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Teva pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Teva Pharmaceutical Industries. Since Teva Pharmaceutical is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Teva Pink Sheet. However, Teva Pharmaceutical's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 17.8 | Real 14.59 | Hype 17.8 | Naive 16.75 |
The real value of Teva Pink Sheet, also known as its intrinsic value, is the underlying worth of Teva Pharmaceutical Company, which is reflected in its stock price. It is based on Teva Pharmaceutical's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Teva Pharmaceutical's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Teva Pharmaceutical Industries helps investors to forecast how Teva pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Teva Pharmaceutical more accurately as focusing exclusively on Teva Pharmaceutical's fundamentals will not take into account other important factors: Teva Pharmaceutical Total Value Analysis
Teva Pharmaceutical Industries is at this time forecasted to have takeover price of 28.75 B with market capitalization of 10.99 B, debt of 19.1 B, and cash on hands of 2.06 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Teva Pharmaceutical fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
28.75 B | 10.99 B | 19.1 B | 2.06 B |
Teva Pharmaceutical Investor Information
The company has price-to-book ratio of 1.1. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Teva Pharmaceutical has Price/Earnings To Growth (PEG) ratio of 0.8. The entity recorded a loss per share of 0.56. The firm last dividend was issued on the 28th of November 2017. Teva Pharmaceutical had 2:1 split on the 11th of December 2002. Based on the analysis of Teva Pharmaceutical's profitability, liquidity, and operating efficiency, Teva Pharmaceutical Industries is not in a good financial situation at this time. It has a very high probability of going through financial hardship in October.Teva Pharmaceutical Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Teva Pharmaceutical has an asset utilization ratio of 33.92 percent. This implies that the Company is making $0.34 for each dollar of assets. An increasing asset utilization means that Teva Pharmaceutical Industries is more efficient with each dollar of assets it utilizes for everyday operations.Teva Pharmaceutical Ownership Allocation
Teva Pharmaceutical shows a total of 1.11 Billion outstanding shares. About 93.93 % of Teva Pharmaceutical outstanding shares are held by general public with 0.77 (%) owned by insiders and only 5.3 % by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Teva Pharmaceutical Profitability Analysis
The company reported the revenue of 14.93 B. Net Loss for the year was (2.41 B) with profit before overhead, payroll, taxes, and interest of 6.97 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Teva Pharmaceutical's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Teva Pharmaceutical and how it compares across the competition.
About Teva Pharmaceutical Valuation
The pink sheet valuation mechanism determines Teva Pharmaceutical's current worth on a weekly basis. Our valuation model uses a comparative analysis of Teva Pharmaceutical. We calculate exposure to Teva Pharmaceutical's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Teva Pharmaceutical's related companies.Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel. TEVA PHARMACEUTICAL is traded on OTC Exchange in the United States.
8 Steps to conduct Teva Pharmaceutical's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Teva Pharmaceutical's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Teva Pharmaceutical's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Teva Pharmaceutical's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Teva Pharmaceutical's revenue streams: Identify Teva Pharmaceutical's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Teva Pharmaceutical's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Teva Pharmaceutical's growth potential: Evaluate Teva Pharmaceutical's management, business model, and growth potential.
- Determine Teva Pharmaceutical's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Teva Pharmaceutical's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Teva Pharmaceutical Growth Indicators
Investing in growth stocks can be very risky. If the company such as Teva Pharmaceutical does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 1.1 B | |
| Quarterly Earnings Growth Y O Y | -0.808 | |
| Forward Price Earnings | 3.4317 | |
| Retained Earnings | -12.9 B | |
| Retained Earnings Total Equity | -12.9 B |
Complementary Tools for Teva Pink Sheet analysis
When running Teva Pharmaceutical's price analysis, check to measure Teva Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Teva Pharmaceutical is operating at the current time. Most of Teva Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Teva Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Teva Pharmaceutical's price. Additionally, you may evaluate how the addition of Teva Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |